Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
Medical College of Wisconsin
Summary
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Description
B-cell Acute lymphoblastic leukemia (B-ALL) is a potentially curable malignancy in the pediatric population. In contrast, the outcomes of adults with B-ALL have remained historically poor due to risk of relapse after frontline therapy. Novel agents in the current era have changed the treatment landscape of adults with relapsed/refractory B-ALL with improved tolerability and better outcomes \[1\]. Currently, blinatumomab (CD3-CD19 bispecific molecule) and inotuzumab (CD22 antibody drug conjugate) are approved for the management of patients with relapsed/refractory B-ALL. With the superior effic…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients Exclusion Criteria: * N/A
Location
- Medical College of WisconsinMilwaukee, Wisconsin